Michiel Tent summarises 6 abstracts from the AAN 2021 Virtual Annual Meeting:
- COVID-19 Keynote Address - Walter J. Koroshetz, MD, FAAN, and Anthony S. Fauci, MD. AAN 2021 Virtual, Neuro-COVID plenary session.
- Global impact of the COVID-19 pandemic on stroke care and intravenous thrombolysis - Nguyen TN, et al. AAN 2021 Virtual, Abstract N3.002.
- Persistent chemosensory dysfunction associated with COVID-19 infection in a cohort of over 700 healthcare workers - BussiĂšre N, et al. AAN 2021 Virtual, Abstract S21.005.
- Frequency and predictors of obstructive sleep apnea in a cognitively impaired clinic population - Colelli DR. AAN 2021 Virtual, Abstract S9.003.
- Fetal antiseizure medication effects on neuropsychological outcomes at age 3 years in the MONEAD study - Meador K, et al. AAN 2021 Virtual, Abstract S1.001.
- A genome-wide association study highlights a possible involvement of mast cells and neutrophils in disease activity in multiple sclerosis - Giordano A, et al. AAN 2021 Virtual, Abstract S11.002.
Posted on
Previous Article
« Web-based patient education cuts down upper GI endoscopy for dyspepsia Next Article
Intracerebral hemorrhage a new risk marker for arterial ischemic events »
« Web-based patient education cuts down upper GI endoscopy for dyspepsia Next Article
Intracerebral hemorrhage a new risk marker for arterial ischemic events »
Table of Contents: AAN 2021
Featured articles
Letter from the Editor
Interview with AAN President Dr James C. Stevens
COVID-19 and Neurology
The neurological impact of COVID-19
Chemosensory dysfunction often persistent after COVID-19
Pandemic results in decreased global stroke care
Stroke uncommon in critically ill COVID-19 patients
Cognitive Impairment and Dementias
Obstructive sleep apnoea associated with lower cognition
NfL is a better marker for neurodegeneration than T-tau
Monoclonal antibody rapidly reduces brain amyloid
Epilepsy
Extraordinary transformation of epilepsy care in Ontario
No neurodevelopmental effects of foetal antiseizure medication
Migraine and Other Headaches
Long-term safety of atogepant as migraine prophylaxis
Multiple Sclerosis
Dysmetabolism may drive MS progression
Predicting long-term prognosis in paediatric MS patients
Neuromuscular Disorders
Functional and survival benefits of AMX0035 in ALS
Parkinsonâs Disease and Other Movement Disorders
Autoimmune mechanisms implicated in Parkinsonâs disease
Novel nonâD2-receptor-binding treatment for Parkinsonâs disease psychosis
Troriluzole for spinocerebellar ataxia
Stroke
Can linoleic acid help prevent stroke?
No association between SSRIs and risk of ICH
Other Topics
Vutrisiran for hATTR amyloidosis with polyneuropathy
10 kHz spinal cord stimulation for painful diabetic neuropathy
Related Articles
June 15, 2022
Sotagliflozin SCORED MACE benefit
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com